Trial Profile
Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Filgrastim; Pegfilgrastim; Prednisone; Vincristine
- Indications Burkitt's lymphoma; Leukaemia; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 18 Sep 2023 Status changed from active, no longer recruiting to completed.
- 07 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.
- 07 Dec 2022 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2023.